Merck & Co. (MRK) delivered encouraging news Thursday for parents of vulnerable children: its RSV antibody treatment appears to hold up safely through a second respiratory virus season.

The pharmaceutical giant presented findings from the second RSV season of its Phase 3 SMART trial at the RSVVW Conference, showing that Enflonsia (clesrovimab) maintained a safety profile consistent with what researchers observed during the first season. More importantly, the monoclonal antibody achieved serum concentrations comparable to those seen in healthy infants from earlier studies, suggesting the treatment could effectively protect high-risk children who need coverage beyond their initial RSV season.

This matters because Enflonsia currently has FDA approval only for infants during their first RSV season, where it's designed to provide about five months of protection. But some children, particularly those with underlying health conditions or premature births, remain vulnerable in their second year of life. Merck plans to share this new data with the FDA to pursue an expanded indication for these higher-risk kids.

Building on Earlier Success

The original FDA approval in June 2025 came on the strength of interim data from the first RSV season of the SMART trial, combined with results from the pivotal Phase 2b/3 CLEVER trial. Those studies established that the antibody works for standard-risk infants in their first season. Now Merck is making the case that it can do more.

The trial enrolled children under 2 years of age, tracking both safety signals and whether the antibody maintained therapeutic levels in the bloodstream. The consistency across both measures suggests the treatment could become a repeat option for families dealing with conditions like congenital heart disease or chronic lung issues that make RSV particularly dangerous.

Competitive Landscape Heats Up

Merck isn't alone in the RSV prevention space. GSK plc (GSK) presented new data Wednesday for AREXVY, its RSV vaccine targeting older adults. The study showed 75.6% vaccine effectiveness against RSV-related hospitalization at a median follow-up of 5.6 months post-vaccination. Perhaps more striking, exploratory analysis suggested 63.1% effectiveness against major adverse cardiovascular events, an intriguing finding given RSV's potential to stress the heart.

The two approaches target different populations, but both companies are racing to establish their products as the standard of care in their respective markets.

Stock Performance and Market Outlook

Investors have taken notice of Merck's momentum. Shares currently trade 5.9% above the 20-day simple moving average and 11.5% above the 100-day SMA, indicating sustained upward pressure. Over the past year, the stock has climbed 42.13% and now sits much closer to its 52-week high than low.

Technical indicators paint a mixed but generally positive picture. The RSI stands at 69.29, hovering in neutral territory just shy of overbought levels. Meanwhile, MACD at 3.7853 sits comfortably above its signal line of 3.3955, suggesting bullish momentum hasn't exhausted itself yet.

Key levels to watch: resistance at $123.50 and support at $120.00.

What Analysts Are Saying

Wall Street maintains a Buy rating on Merck with an average price target of $119.95. Recent moves include:

• Guggenheim: Buy rating with target raised to $140.00 (Feb. 6)
• Citigroup: Neutral rating with target raised to $120.00 (Feb. 4)
• Cantor Fitzgerald: Neutral rating with target raised to $120.00 (Feb. 4)

Even the neutral-rated analysts are raising their price targets, suggesting growing confidence in the company's trajectory.

Shares were down slightly at $121.62 in premarket trading Thursday, essentially flat on the day.